White label – Pompe disease - ClinicalTrials.eu

Study on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis

Not recruiting

3 1 1
Investigated Diseases:
- Eosinophilic oesophagitis
Investigated Drugs:
- Cendakimab
+1
Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months – 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors

Not recruiting

1 1 1 1
Investigated Diseases:
Investigated Drugs:
+1
Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)

Not recruiting

3 1 1 1
Investigated Drugs:
Study on Long-Term Safety of Donidalorsen for Patients with Hereditary Angioedema

Not recruiting

3 1 1
Investigated Drugs:
- Donidalorsen
+2
Study on Guselkumab for Treating Active Psoriatic Arthritis in Patients with Inadequate Response to One Prior Anti-TNF Agent

Not recruiting

3 1
Investigated Diseases:
- Psoriatic arthropathy
Investigated Drugs:
- Guselkumab
Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Not recruiting

3 1 1
Investigated Drugs:
+1
Study Comparing Sacituzumab Govitecan with Standard Treatment for Patients with Metastatic Colorectal Cancer

Not recruiting

4 1 1 1
Investigated Diseases:
- Colorectal cancer metastatic
Investigated Drugs:
Study on the Effects of GLM101 for Patients with PMM2-CDG

Not recruiting

2 1 1
Investigated Diseases:
- Metabolic disorder
Investigated Drugs:
- Alfa-D-Mannopyranosyl Phosphate Dipotassium
Study on Stopping Solifenacin and Mirabegron for Children with Daytime Urinary Incontinence

Not recruiting

3 1 1 1
Investigated Diseases:
- Incontinence
- Urinary incontinence
Investigated Drugs:
- Mirabegron
- Solifenacin Succinate
Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

Not recruiting

3 1
Investigated Drugs:
- Resmetirom
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies